Northern Oak Wealth Management Inc. grew its position in Merck & Company, Inc. (NYSE:MRK) by 2.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,813 shares of the company’s stock after acquiring an additional 604 shares during the quarter. Northern Oak Wealth Management Inc.’s holdings in Merck & were worth $1,831,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Vigilant Capital Management LLC lifted its holdings in shares of Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares during the period. Harbour Capital Advisors LLC acquired a new stake in shares of Merck & during the first quarter worth $127,000. Gradient Investments LLC lifted its holdings in shares of Merck & by 41.3% during the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock worth $147,000 after purchasing an additional 674 shares during the period. Pinnacle Bank acquired a new stake in shares of Merck & during the first quarter worth $152,000. Finally, Dillon & Associates Inc. acquired a new stake in shares of Merck & during the first quarter worth $206,000. 73.02% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Merck & Company, Inc. (MRK) Shares Bought by Northern Oak Wealth Management Inc.” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/13/merck-company-inc-mrk-shares-bought-by-northern-oak-wealth-management-inc.html.
Shares of Merck & Company, Inc. (MRK) traded down 0.03% on Wednesday, hitting $65.44. The stock had a trading volume of 2,017,667 shares. The firm has a market cap of $178.48 billion, a P/E ratio of 35.43 and a beta of 0.81. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The company’s 50-day moving average price is $63.05 and its 200 day moving average price is $63.70.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.93 earnings per share. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Thursday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.87%. Merck &’s dividend payout ratio (DPR) is 76.11%.
Several brokerages recently weighed in on MRK. BidaskClub downgraded Merck & from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. BMO Capital Markets reaffirmed an “outperform” rating and set a $73.00 price target (down from $74.00) on shares of Merck & in a report on Monday, July 24th. Citigroup Inc. set a $65.00 price target on Merck & and gave the stock a “hold” rating in a report on Wednesday, July 5th. Zacks Investment Research downgraded Merck & from a “buy” rating to a “hold” rating in a report on Thursday, May 25th. Finally, Jefferies Group LLC reaffirmed a “sell” rating and set a $51.00 price target on shares of Merck & in a report on Wednesday, May 24th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Merck & currently has a consensus rating of “Hold” and an average target price of $70.00.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.